Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2017

Jan 31, 2018

SELL
$35.44 - $63.76 $512,993 - $922,926
-14,475 Closed
0 $0
Q3 2017

Oct 31, 2017

BUY
$53.83 - $67.75 $779,189 - $980,681
14,475
14,475 $938,000

Others Institutions Holding PRTA

About PROTHENA CORP PUBLIC LTD CO


  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $714M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Dupont Capital Management Corp Portfolio

Follow Dupont Capital Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Dupont Capital Management Corp with notifications on news.